Charles Béguelin

Charles Béguelin

Auto-generated profile, based on publicly available information

Charles Béguelin

Department of Infectious Diseases Inselspital, Bern University Hospital, University of Bern Bern Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2020 in Liver International
Verified
Journal Article
Open access
PDF file
BSBernard Surial
Bernard Surial
DWDominik Wyser
Dominik Wyser
CBCharles Béguelin
Charles Béguelin
ARAdrià Ramírez‐Mena
Adrià Ramírez‐Mena
ARAndri Rauch
Andri Rauch
GWGilles Wandeler
Gilles Wandeler
Background & Aims: Chronic hepatitis B virus (HBV) infection accounts for 30%‐50% of cirrhosis related deaths in sub‐Saharan Africa (SSA). Since HBV‐related cirrhosis is an indication for immediate antiviral therapy and cancer surveillance, we aimed to estimate the prevalence of cirrhosis among treatment‐naïve patients with chronic HBV infection in SSA.Methods: We performed a systematic review of published articles which evaluated liver fibrosis stage among treatment‐naïve HBV‐infected individuals who presented to care in SSA. Our primary outcome was the prevalence of cirrhosis in HBsAg‐positive persons, which was estimated using random‐effects meta‐analysis. Risk factors for cirrhosis were explored using subgroup‐analyses and multivariable meta‐regression.Results: Of 2129 articles identified, 17 met our eligibility criteria. The studies described 22 cohorts from 13 countries, including 13 cohorts (3204 patients) with chronic HBV mono‐infection and nine cohorts (688 patients) with HIV/HBV‐coinfection. Liver fibrosis was assessed using transient elastography (10 cohorts), APRI score (11 cohorts), and Fibrotest (one cohort). The pooled prevalence of cirrhosis was 4.1% (95% confidence interval [CI] 2.6‐6.4) among studies from primary care facilities or general population, compared to 12.7% (95% CI 8.6‐18.3) in studies performed in referral or tertiary care facilities (adjusted odds ratio 0.29, 95% CI 0.15‐0.56). We found no association between cirrhosis and age, gender, fibrosis test used or HIV‐coinfection.Conclusions: Depending on the setting, between 4% and 13% of HBV‐infected individuals in SSA have cirrhosis and need immediate antiviral therapy. These estimates should be considered when planning HBV treatment strategies and resource allocation.

21 January 2023 in Liver International
Verified
Journal Article
Open access
CBCharles Béguelin
Charles Béguelin
AAAndrew Atkinson
Andrew Atkinson
ABAnders Boyd
Anders Boyd
KFKarolin Falconer
Karolin Falconer
NKNikolai Kirkby
Nikolai Kirkby
FSfor EuroSIDA and SHCS
for EuroSIDA and SHCS
Background and Aims: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes.Methods: All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti‐HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV‐positive and HDV‐negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver‐related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause‐specific multivariable Cox regression.Results: Of 2793 HBsAg‐positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%–17.1%) and 66% (132/200) of HDV‐positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%–55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%–5.9%) among other participants. During a median follow‐up of 10.8 years (interquartile range 5.6–17.8), 82 (34.6%) HDV‐positive and 265 (20.1%) HDV‐negative individuals died. 41.5% (34/82) of deaths were liver‐related in HDV‐positive individuals compared to 17.7% (47/265) in HDV‐negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2–2.1), liver‐related death (2.9, 1.6–5.0) and HCC (6.3, 2.5–16.0).Conclusion: We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver‐related mortality and HCC incidence.

11 February 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCharles Béguelin
Charles Béguelin
NFNicole Friolet
Nicole Friolet
DMDarius Moradpour
Darius Moradpour
RSRoland Sahli
Roland Sahli
FSFranziska Suter-Riniker
Franziska Suter-Riniker
FSfor the Swiss HIV Cohort Study
for the Swiss HIV Cohort Study
We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.

23 August 2017 in Liver International
Verified
Journal Article
Closed access
PDF file
CBCharles Béguelin
Charles Béguelin
ASAnnatina Suter
Annatina Suter
EBEnos Bernasconi
Enos Bernasconi
JFJan Fehr
Jan Fehr
HKHelen Kovari
Helen Kovari
TSThe Swiss HIV Cohort Study
The Swiss HIV Cohort Study

12 April 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JDJosé Damas
José Damas
AMAline Munting
Aline Munting
JFJacques Fellay
Jacques Fellay
DHDavid Haerry
David Haerry
Catia MarzoliniCatia Marzolini
Catia Marzolini
BSBernard Surial
Bernard Surial
Background: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study. Methods: We included participants who received at least 6 months of TAF-containing ART between January 2016 and March 2023. Using multivariable mixed-effect models, changes in weight and lipid levels were compared between individuals who continued TAF and those who switched to one of the following TAF-free regimens: (1) tenofovir disoproxil fumarate (TDF)-based ART, (2) dolutegravir/lamivudine (DTG/3TC), or (3) long-acting cabotegravir/rilpivirine (CAB/RPV). Results: Of 6555 participants (median age 54 years, 24.3% female, 13% Black), 5485 (83.7%) continued, and 1070 (16.3%) stopped TAF. Overall, discontinuing TAF was associated with an adjusted mean weight change of −0.54 kg (95% confidence interval [CI] −.98 to −.11) after 12 months. In stratified analyses, switching from TAF to TDF led to an adjusted mean weight decrease of −1.84 kg (95% CI −2.72 to −.97), and to a decrease in mean total cholesterol (−0.44 mmol/L) and triglycerides (−0.38 mmol/L) after 12 months. Switching from TAF-based ART to DTG/3TC (−0.17 kg, 95% CI −.82 to .48) or long-acting CAB/RPV (−0.64 kg, 95% CI −2.16 to .89) did not lead to reductions in weight. Conclusions: Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.

26 June 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLuisa Salazar-Vizcaya
Luisa Salazar-Vizcaya
GWGilles Wandeler
Gilles Wandeler
JFJan Fehr
Jan Fehr
DBDominique Braun
Dominique Braun
MCMatthias Cavassini
Matthias Cavassini
ARAndri Rauch
Andri Rauch
In the Swiss HIV Cohort Study, the number of people who inject drugs with replicating hepatitis C virus (HCV) infection decreased substantially after the introduction of direct-acting antivirals (DAAs). Among men who have sex with men, the increase in DAA uptake and efficacy was counterbalanced by frequent incident HCV infections.